TY - JOUR
T1 - Mega-Analysis of Gray Matter Volume in Substance Dependence: General and Substance-Specific Regional Effects.
AU - S, Mackey
AU - N, Allgaier
AU - B, Chaarani
AU - P, Spechler
AU - C, Orr
AU - J, Bunn
AU - NB, Allen
AU - N, Alia-Klein
AU - A, Batalla
AU - S, Blaine
AU - S, Brooks
AU - E, Caparelli
AU - YY, Chye
AU - J, Cousijn
N1 - Funding Information:
Supported by NIDA grant 1R21DA038381 to Dr. Garavan and by NIH grant U54 EB 020403 with funds provided for the trans-NIH Big Data to Knowledge (BD2K) initiative. Data collection: Dr. Korucuoglu received support for the Neuro-ADAPT study from VICI grant 453.08.01 from the Netherlands Organization for Scientific Research (NWO), awarded to Reinout W. Wiers. Drs. Schmaal and Veltman received funding from Netherlands Organization for Health Research and Development (ZonMW) grant 31160003 from NWO. Drs. Sjoerds and Veltman received funding from ZonMW grant 31160004 from NWO. Drs. Goudriaan and van Holst received funding from ZonMW grant 91676084 from NWO. Drs. Luijten and Veltman received funding from VIDI grant 016.08.322 from NWO, awarded to Ingmar H.A. Franken. Drs. Cousijn and Goudriaan received funding for the Cannabis Prospective study from ZonMW grant 31180002 from NWO. Drs. Garavan and Foxe received funds from NIDA grant R01-DA014100. Dr. Li received funding from NIDA grants R01AA021449, R01DA023248, and K25DA040032. Dr. London was supported by NIDA grant R01 DA020726, the Thomas P. and Katherine K. Pike Chair in Addiction Studies, the Endowment From the Marjorie Greene Family Trust, and UCLA contract 20063287 with Philip Morris USA. Data collection by Dr. Momenan was supported by the Intramural Clinical and Biological Research Program of the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Dr. Morales was supported by NIDA grant T32 DA024635. Dr. Paulus received funding from NIMH grant R01 DA018307. Dr. Stein was supported by the Intramural Research Program of NIDA and NIH. Dr. Sinha received funds from NIDA (PL30-1DA024859-01), the NIH National Center for Research Resources (UL1-RR24925-01), and NIAAA (R01-AA013892). Dr. Solowij received funding from the Clive and Vera Ramaciotti Foundation for Biomedical Research National and Health and Medical Research Council Project grant 459111 and was supported by Australian Research Council Future Fellowship FT110100752. Prof. Yücel was supported by National Health and Medical Research Council Fellowship 1117188 and the David Winston Turner Endowment Fund. The authors thank Alex Wonnell, Alexandra Ivanciu, Noah Markowitz, Michael Lawler, Styles Crawford, and Mitchell Snowe at the University of Vermont for excellent technical assistance in tabulating the behavioral data and performing final quality control checks on the neuroimaging data. Dr. Sinha has served on the scientific advisory board of Embera Neurotherapeutics. Prof. Yücel has received funding from several law firms in relation to expert witness reports. Dr. Hibar is an employee at Janssen Research and Development. The other authors report no financial relationships with commercial interests.
Funding Information:
Supported by NIDA grant 1R21DA038381 to Dr. Garavan and by NIH grant U54 EB 020403 with funds provided for the trans-NIH Big Data to Knowledge (BD2K) initiative. Data collection: Dr. Korucuoglu received support for the Neuro-ADAPT study from VICI grant 453.08.01 from the Netherlands Organization for Scientific Research (NWO), awarded to Reinout W. Wiers. Drs. Schmaal and Veltman received funding from Netherlands Organization for Health Research and Development (ZonMW) grant 31160003 from NWO. Drs. Sjoerds and Veltman received funding from ZonMW grant 31160004 from NWO. Drs. Goudriaan and van Holst received funding from ZonMW grant 91676084 from NWO. Drs. Luijten and Veltman received funding from VIDI grant 016.08.322 from NWO, awarded to Ingmar H.A. Franken. Drs. Cousijn and Goudriaan received funding for the Cannabis Prospective study from ZonMW grant 31180002 from NWO. Drs. Garavan and Foxe received funds from NIDA grant R01-DA014100. Dr. Li received funding from NIDA grants R01AA021449, R01DA023248, and K25DA040032. Dr. London was supported by NIDA grant R01 DA020726, the Thomas P. and Katherine K. Pike Chair in Addiction Studies, the Endowment From the Marjorie Greene Family Trust, and UCLA contract 20063287 with Philip Morris USA. Data collection by Dr. Momenan was supported by the Intramural Clinical and Biological Research Program of the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Dr. Morales was supported by NIDA grant T32 DA024635. Dr. Paulus received funding from NIMH grant R01 DA018307. Dr. Stein was supported by the Intramural Research Program of NIDA and NIH. Dr. Sinha received funds from NIDA (PL30-1DA024859-01), the NIH National Center for Research Resources (UL1-RR24925-01), and NIAAA (R01-AA013892). Dr. Solowij received funding from the Clive and Vera Ramaciotti Foundation for Biomedical Research National and Health and Medical Research Council Project grant 459111 and was supported by Australian Research Council Future Fellowship FT110100752. Prof. Yücel was supported by National Health and Medical Research Council Fellowship 1117188 and the David Winston Turner Endowment Fund.
Publisher Copyright:
© 2019 American Psychiatric Association. All Rights Reserved.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Objective: Although lower brain volume has been routinely observed in individuals with substance dependence compared with nondependent control subjects, the brain regions exhibiting lower volume have not been consistent across studies. In addition, it is not clear whether a common set of regions are involved in substance dependence regardless of the substance used or whether some brain volume effects are substance specific. Resolution of these issues may contribute to the identification of clinically relevant imaging biomarkers. Using pooled data from 14 countries, the authors sought to identify general and substance-specific associations between dependence and regional brain volumes. Method: Brain structure was examined in a mega-analysis of previously published data pooled from 23 laboratories, including 3,240 individuals, 2,140 of whom had substance dependence on one of five substances: alcohol, nicotine, cocaine, methamphetamine, or cannabis. Subcortical volume and cortical thickness in regions defined by FreeSurfer were compared with nondependent control subjects when all sampled substance categories were combined, as well as separately, while controlling for age, sex, imaging site, and total intracranial volume. Because of extensive associations with alcohol dependence, a secondary contrast was also performed for dependence on all substances except alcohol. An optimized split-half strategy was used to assess the reliability of the findings. Results: Lower volume or thickness was observed in many brain regions in individuals with substance dependence. The greatest effects were associated with alcohol use disorder. A set of affected regions related to dependence in general, regardless of the substance, included the insula and the medial orbitofrontal cortex. Furthermore, a support vector machine multivariate classification of regional brain volumes successfully classified individuals with substance dependence on alcohol or nicotine relative to nondependent control subjects. Conclusions: The results indicate that dependence on a range of different substances shares a common neural substrate and that differential patterns of regional volume could serve as useful biomarkers of dependence on alcohol and nicotine.
AB - Objective: Although lower brain volume has been routinely observed in individuals with substance dependence compared with nondependent control subjects, the brain regions exhibiting lower volume have not been consistent across studies. In addition, it is not clear whether a common set of regions are involved in substance dependence regardless of the substance used or whether some brain volume effects are substance specific. Resolution of these issues may contribute to the identification of clinically relevant imaging biomarkers. Using pooled data from 14 countries, the authors sought to identify general and substance-specific associations between dependence and regional brain volumes. Method: Brain structure was examined in a mega-analysis of previously published data pooled from 23 laboratories, including 3,240 individuals, 2,140 of whom had substance dependence on one of five substances: alcohol, nicotine, cocaine, methamphetamine, or cannabis. Subcortical volume and cortical thickness in regions defined by FreeSurfer were compared with nondependent control subjects when all sampled substance categories were combined, as well as separately, while controlling for age, sex, imaging site, and total intracranial volume. Because of extensive associations with alcohol dependence, a secondary contrast was also performed for dependence on all substances except alcohol. An optimized split-half strategy was used to assess the reliability of the findings. Results: Lower volume or thickness was observed in many brain regions in individuals with substance dependence. The greatest effects were associated with alcohol use disorder. A set of affected regions related to dependence in general, regardless of the substance, included the insula and the medial orbitofrontal cortex. Furthermore, a support vector machine multivariate classification of regional brain volumes successfully classified individuals with substance dependence on alcohol or nicotine relative to nondependent control subjects. Conclusions: The results indicate that dependence on a range of different substances shares a common neural substrate and that differential patterns of regional volume could serve as useful biomarkers of dependence on alcohol and nicotine.
UR - http://www.scopus.com/inward/record.url?scp=85061044348&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2018.17040415
DO - 10.1176/appi.ajp.2018.17040415
M3 - Article
C2 - 30336705
SN - 0002-953X
VL - 176
SP - 119
EP - 128
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 2
ER -